Par Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹99.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.8%+2.8% vs market

Pharmaceuticals peers, median of 147sector-0.9%+2.9% vs sector

On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 2.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0-0.8+2.8-0.9+2.9

Next day

+4.0-0.7+4.7-0.6+4.6

+4.2-0.6+4.8-0.3+4.4

+2.1+0.0+2.0-0.6+2.6

+0.1-0.8+0.9-0.6+0.7

+2.0+0.7+1.3-0.9+2.9

+0.0+1.9-1.9-0.1+0.1

15d

+2.3+0.9+1.4-0.8+3.2

+4.0+1.7+2.3-1.0+5.0

+5.4+0.2+5.1-1.3+6.7

-1.2+0.8-2.0-4.7+3.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Par Drugs and Chemicals Limited submitted its unaudited standalone financial results for the quarter ended June 30, 2025. Revenue from operations rose to ₹2,604.64 lakhs from ₹2,260.56 lakhs in Q1 FY25, a growth of about 15% year-on-year. Profit after tax jumped roughly 31% YoY to ₹332.81 lakhs, with EPS improving to ₹2.70 from ₹2.06. Profit before tax came in at ₹447.78 lakhs, up 32% YoY, supported by higher other income of ₹183.67 lakhs. The statutory auditor (Sarupria Somani & Associates) issued a clean limited review report with no qualifications. The board also approved renewal of a ₹161 lakh banking facility with Kotak Mahindra Bank with no change in limits.

Likely market impact

Strong ~31% YoY PAT growth and margin expansion indicate healthy operational performance, which is a positive signal for shareholders. The clean auditor report and routine banking facility renewal carry no negative concerns, but the modest revenue growth of ~15% (below 20%) tempers the upside narrative.